
|Videos|March 8, 2022
Management of dermatologic adverse events with apalutamide in prostate cancer
Author(s)Urology Times staff
“The majority of patients were able to stay on the dose of the apalutamide,” says Mario E. Lacouture, MD.
Advertisement
In this video, Mario E. Lacouture, MD, discusses the background, findings, and takeaways of the Journal of Urology study, “Dermatologic adverse events in prostate cancer patients treated with androgen receptor inhibitor apalutamide.” Lacouture is a dermatologist at Memorial Sloan Kettering Cancer Center in New York, New York.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
The UroOnc Minute: Cribriform Histology in Prostate Cancer, With Tyler Seibert, MD, PhD
2
CMS' 2027 PFS proposed rule: Modifier -25 cuts, G2211 overhaul loom
3
Rezūm shows greater 1-year BPH symptom relief vs pharmacotherapy
4
FDA grants breakthrough therapy, fast track designations to kidney cancer imaging agent
5










